<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00951522</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-221-0102</org_study_id>
    <nct_id>NCT00951522</nct_id>
  </id_info>
  <brief_title>A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of GS-9411 in Healthy Male Volunteers</brief_title>
  <official_title>A Phase 1 Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety, Tolerability, and Pharmacokinetics of GS-9411 in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and tolerability of escalating doses of&#xD;
      GS-9411 in healthy male volunteers. GS-9411 is a sodium channel inhibitor, that may restore&#xD;
      airway hydration and mucociliary clearance in the lung.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      GS-9411 is being evaluated as a potential therapy to improve airway hydration and mucociliary&#xD;
      clearance in patients with cystic fibrosis. This study is evaluating the safety and&#xD;
      tolerability of 4 dose levels of GS-9411 as an inhaled product, compared to a matched&#xD;
      placebo.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability of 4 escalating doses of GS-9411 in healthy male volunteers</measure>
    <time_frame>7 Days</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Cystic Fibrosis</condition>
  <condition>Mucociliary Clearance</condition>
  <condition>Airway Hydration</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GS-9411 2.4 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GS-9411 4.8 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GS-9411 7.2 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GS-9411 9.6 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GS-9411</intervention_name>
    <description>Inhaled GS-9411 dissolved in sterile saline</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Inhaled placebo in sterile saline</description>
    <arm_group_label>5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males 18 to 45 years of age&#xD;
&#xD;
          -  No clinically important abnormal physical findings at the screening examination&#xD;
&#xD;
          -  No clinically relevant abnormalities in the results of laboratory screening evaluation&#xD;
&#xD;
          -  Normal (or abnormal but not clinically significant) ECG&#xD;
&#xD;
          -  Normal (or abnormal but not clinically significant) blood pressure (BP) and heart&#xD;
             rate(HR).&#xD;
&#xD;
          -  Body weight between 70 and 125 kg and body mass index (BMI) between 18 and 28 kg/m2.&#xD;
&#xD;
          -  Able to communicate well with the investigator and to comply with the requirements of&#xD;
             the entire study.&#xD;
&#xD;
          -  Provision of written informed consent to participate as shown by a signature on the&#xD;
             volunteer consent form.&#xD;
&#xD;
          -  Non-smokers of at least 6 months duration (&lt; 10 pack/year history) prior to study&#xD;
             entry.&#xD;
&#xD;
          -  Negative for drugs of abuse (including alcohol) at Screening and Day -5.&#xD;
&#xD;
          -  Must be willing to abstain from alcohol and strenuous exercise during the 48-hour&#xD;
             period prior to admission and during the study.&#xD;
&#xD;
          -  Forced expiratory volume in 1 second (FEV1) â‰¥ 80% of predicted normal for age, gender,&#xD;
             and height at Screening and Pre-dose.&#xD;
&#xD;
          -  Normal intraocular pressure between 10 and 21 mm Hg.&#xD;
&#xD;
          -  Male subjects who are sexually active must be willing to use effective barrier&#xD;
             contraception (e.g., condoms) during heterosexual intercourse from Baseline/Day 0&#xD;
             through completion of the study and continuing for at least 90 days from date of last&#xD;
             dose of study drug.&#xD;
&#xD;
          -  Male subjects must refrain from sperm donation from Day 1 through completion of the&#xD;
             study and continuing for at least 90 days from the date of last dose of study drug.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any prior exposure to GS-9411.&#xD;
&#xD;
          -  Administration of any investigational drug in the period 0 to 12 weeks before entry to&#xD;
             the study.&#xD;
&#xD;
          -  A need for any medication during the period 0 to 5 days before entry to the study,&#xD;
             except those deemed by the principal investigator/clinical investigator not to&#xD;
             interfere with the outcome of the study.&#xD;
&#xD;
          -  Existence of any surgical or medical condition which, in the judgment of the clinical&#xD;
             investigator, might interfere with the absorption, distribution, metabolism, or&#xD;
             excretion of the drug.&#xD;
&#xD;
          -  Presence or history of allergy requiring treatment. Hay fever is allowed unless it is&#xD;
             active or has required treatment within the previous 2 months.&#xD;
&#xD;
          -  Donation or loss of greater than 400 mL of blood in the period 0 to 12 weeks before&#xD;
             entry to the study.&#xD;
&#xD;
          -  Serious adverse reaction or hypersensitivity to any drug.&#xD;
&#xD;
          -  Presence or history of any pulmonary diseases (e.g., asthma, emphysema, chronic&#xD;
             bronchitis, cystic fibrosis, bronchiectasis).&#xD;
&#xD;
          -  Consumption of drugs and/or herbal preparations capable of inducing hepatic enzyme&#xD;
             metabolism (e.g., barbiturates, rifampicin, carbamazepine, phenytoin, primidone, or&#xD;
             St. John's Wort) or enzyme-inhibiting agents (e.g., cimetidine) or similar drugs&#xD;
             within 30 days (or 5 half-lives of inducing/inhibiting agent, whichever is longer) of&#xD;
             enrollment in this study.&#xD;
&#xD;
          -  Major surgery within 6 months of the start of this study.&#xD;
&#xD;
          -  Subjects who have experienced a significant upper or lower respiratory tract infection&#xD;
             within the 6 weeks prior to admission.&#xD;
&#xD;
          -  Subjects with significant history of respiratory, renal, hepatic, cardiovascular&#xD;
             (including history of systemic hypertension requiring therapy), metabolic,&#xD;
             neurological, hematological, gastrointestinal, cerebrovascular, or other significant&#xD;
             medical illness or disorder which, in the judgment of the investigator, may interfere&#xD;
             with the study or require treatment which may affect the evaluation of efficacy and&#xD;
             safety of the study drug.&#xD;
&#xD;
          -  Subjects with elevated liver enzyme concentrations at Screening and at Day -1.&#xD;
&#xD;
          -  Hemoglobin level &lt; 130 g/L taken at Screening and at Day -1.&#xD;
&#xD;
          -  Serum potassium &gt; 5 mEq/L taken at Screening and at Day -1.&#xD;
&#xD;
          -  Poor venous access.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Hodsman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nucleus Network Ltd</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nucleus Network, Ltd.</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <study_first_submitted>August 3, 2009</study_first_submitted>
  <study_first_submitted_qc>August 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2009</study_first_posted>
  <last_update_submitted>September 24, 2009</last_update_submitted>
  <last_update_submitted_qc>September 24, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 25, 2009</last_update_posted>
  <responsible_party>
    <name_title>Thomas O'Riordan, MD</name_title>
    <organization>Gilead Sciences, Inc.&lt;/</organization>
  </responsible_party>
  <keyword>Cystic Fibrosis</keyword>
  <keyword>CF</keyword>
  <keyword>Mucociliary Clearance</keyword>
  <keyword>Epithelial Sodium Channel Inhibitor</keyword>
  <keyword>ENaC Inhibitor</keyword>
  <keyword>Airway Hydration</keyword>
  <keyword>Amiloride</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

